BCL2 and acute myeloid leukemia: Based on most AMLs (including KMT2a‐r) having high BCL‐2 expression, VEN‐AZA is now considered standard of care in the treatment of R/R AML in younger adults and in de novo AML in older adults who are not fit for intensive therapy [12].